|篇名||Efficacy of Combined Finasteride and α1-blocker Treatment for Benign Prostatic Hyperplasia after Initial Unsatisfactory Response to α1-blocker|
|作者||歐建慧 、 唐一清 、 林信男 、 蔡宗欣 、 楊文宏 、 張建成 、 鄭鴻琳 、 林永明|
|關鍵字||攝護腺肥大 、 α1腎上腺素阻斷劑 、 finaster ide 、 Benign prostatic hyperplasia 、 α1-blocker 、 finasteride 、 TSCI|
OBJECTIVE: The purpose of our study was to assess the efficacy of a combination of finasteride and alphal-adrenergic antagonist(α1-blocker)for treatment of benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Charts of 69 patients with symptoms of BPH treated at our department from January 1995 to December 1998 with α1-blocker first then in combination with finasteride (ProscarR 5 mg/day) owing to the unsatisfactory subjective response to the initial α1-blocker were retrospectively reviewed. Data were collected with regards to prostate volume, uroflow rate, and PSA levels before and after finasteride. Changes in prostate volume, PSA level, and maximum uroflow rate were recorded and analyzed for each patient RESULTS: There was a statistically significant decrease in prostate volume and prostate specific antigen level after combination therapy. A mean decrease in prostate volume of 20%±14% was achieved in the first year and 17%±17% in the second year of combination therapy. Mean reductions of 47%± 48% and 57%±34% in serum PSA levels were achieved in the first and second years, respectively. For maximal uroflow rate (Qmax), a significant increase from combination therapy was observed only in patients with baseline PSA values greater than 4 ng/ml and prostate volumes greater than 35cm3 in the first year of treatment (mean 1.1±3.0 and 1.8±3.3ml/s increase, respectively). However, all patients showed improvement in symptoms and quality of life. CONCLUSIONS: Based on our observations, patients with higher baseline PSA levels and larger prostate volumes benefited the most from a combination of finasteride and α1-blocker for treatment of BPH.